



## RESEARCH SEMINAR IN EVIDENCE-BASED PSYCHIATRY

### "Missing evidence and publication bias"

Date: 7<sup>th</sup> December 2023 from 08.30 – 11.30 hrs (CET)

Venue: Online

An increased focus on high quality evidence-based individualized treatment in the psychiatry is supported by the report in 2015 by the Ministry of Health, Ministry for Children, Gender Equality, Integration and Social Affairs (now Ministry of Social Affairs and Senior Citizens), and the Ministry of Higher Education and Science. In the agreement for the coming 10 years for psychiatry strengthening evidence based treatment environments is described as important.

Region Zealand established the Center for Evidence-Based Psychiatry (CEBP) in 2018. The main objective of the center is to support and promote evidence-based practice in psychiatry by conducting systematic reviews and meta-analyses.

In this seminar, we will have a presentation on the Cochrane ROBME tool (a tool for assessing bias in systematic reviews regarding missing evidence in meta-analyses, pairwise syntheses, or single-study syntheses) by Matthew Page, Senior Research Fellow and Deputy Head of the Methods in Evidence Synthesis Unit in the School of Public Health and Preventive Medicine at Monash University, Australia. Furthermore, we will have a presentation by Gustav Nilsson, Associate Professor, Karolinska Institute, Sweden and by stud pscyh. Magnus Tang Kristensen, Center for Evidence-based Psychiatry, Denmark.

The seminar is free of charge. Register your participation no later than December 6<sup>th</sup>.

An Outlook invite with Zoom link will be sent out to participants one week before the event.

Chair: Professor Ole Jakob Storebø

#### PROGRAM

- 08.30 – 08.35 Introduction to Evidence-Based Psychiatry by Ole Jakob Storebø
- 08.35 – 09.15 *About ROBME by Matthew Page*
- 09.15 – 09.40 Q&A and discussion
- 09.40 – 09.55 Break
- 09.55 – 10.35 *Reporting of registered clinical trials in the Nordic countries by Gustav Nilsson*
- 10.35 – 10.50 *Reporting of registered clinical trials assessing the methylphenidate by Magnus Kristensen*
- 10.50 – 11.20 Q&A and discussion
- 11.20 – 11.30 Closing comments by Ole Jakob Storebø